Trgovina Eagle Pharm - EGRX CFD
Dodaj med priljubljene- Povzetek
- Zgodovinski podatki
- Dogodki
- Izkaz poslovnega izida
- Bilanca stanja
- Denarni tok
- Lastništvo
Pogoji trgovanja
| Razmik | - | ||||||||
|
Nočna pristojbina za nakup
Long position overnight fee
Pojdi na platformo | -0.030779% | ||||||||
|
Nočna pristojbina za prodajo
Short position overnight fee
Pojdi na platformo | -0.013666% | ||||||||
| Čas nočne pristojbine | 22:00 (UTC) | ||||||||
| Min. tržena količina | 1 | ||||||||
| Valuta | USD | ||||||||
| Kritje | 20% | ||||||||
| Borza | United States of America | ||||||||
| Provizija na trgovanje | 0% |
*Information provided by Capital.com
Ključni statistični podatki
| Predhodno. Zapri* | N/A |
| Odpri* | N/A |
| Enoletna sprememba* | N/A |
| Dnevni razpon* | N/A |
| Razpon 52 wk | 24.35-53.78 |
| Povprečni obseg (10 dni) | 128.04K |
| Povprečni obseg (3 meseci) | 3.10M |
| Tržna kapitalizacija | 436.16M |
| Razmerje P/E | 20.24 |
| Število delnic v obtoku | 13.02M |
| Prihodki | 298.23M |
| EPS | 1.66 |
| Dividenda (donosnost v %) | N/A |
| Beta | 0.89 |
| Datum naslednjega zaslužka | Mar 6, 2023 |
Vse podatke je zagotovil Refinitiv, razen podatkov, označenih z zvezdico, ki so *podatki, ki jih je zagotovil Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Zapiranje | Change | Change (%) | Odpiranje | High | Low |
|---|
Eagle Pharm Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Letni
- Četrtletno
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Skupni prihodki | 189.482 | 236.707 | 213.312 | 195.892 | 187.802 | 171.546 |
| Prihodki | 189.482 | 236.707 | 213.312 | 195.892 | 187.802 | 171.546 |
| Celotni stroški prihodkov | 55.306 | 57.186 | 61.916 | 60.897 | 45.465 | 42.18 |
| Bruto dobiček | 134.176 | 179.521 | 151.396 | 134.995 | 142.337 | 129.366 |
| Celotni odhodki iz poslovanja | 136.131 | 162.717 | 176.696 | 174.077 | 154.848 | 168.777 |
| Celotna prodaja/splošni/upravni stroški Odhodki | 52.313 | 71.416 | 60.509 | 76.37 | 78.598 | 75.322 |
| Raziskave in razvoj | 30.262 | 32.607 | 44.419 | 36.81 | 30.785 | 51.275 |
| Nenavadni odhodki (prihodki) | -1.75 | 8.885 | 10.615 | 0 | 0 | |
| Prihodki iz poslovanja | 53.351 | 73.99 | 36.616 | 21.815 | 32.954 | 2.769 |
| Prihodki (odhodki) od obresti, neto Neoperativni | 0.076 | -1.045 | -2.578 | -0.517 | -2.015 | -7.275 |
| Drugo, neto | 0 | 0.7 | -8.262 | -0.042 | ||
| Čisti dobiček pred obdavčitvijo | 53.427 | 72.945 | 34.038 | 21.998 | 22.677 | -4.548 |
| Čisti dobiček po davkih | 81.453 | 55.343 | 31.903 | 14.313 | 11.989 | -8.627 |
| Čisti dobiček pred dodatnimi postavkami | 81.453 | 55.343 | 31.903 | 14.313 | 11.989 | -8.627 |
| Čisti dobiček | 81.453 | 51.943 | 31.903 | 14.313 | 11.989 | -8.627 |
| Total Adjustments to Net Income | 0 | |||||
| Prihodek, ki je na razpolago navadnim delničarjem, brez dodatnih postavk | 81.453 | 55.343 | 31.903 | 14.313 | 11.989 | -8.627 |
| Prihodek, ki je na razpolago skupnemu dobičku, vključno z dodatnimi postavkami | 81.453 | 51.943 | 31.903 | 14.313 | 11.989 | -8.627 |
| Popravljen čisti dobiček | 81.453 | 51.943 | 31.903 | 14.313 | 11.989 | -8.627 |
| Popravljene ponderirane povprečne delnice | 16.4341 | 15.9082 | 15.2787 | 14.1387 | 13.7714 | 13.0511 |
| Popravljen dobiček na delnico brez upoštevanja izrednih postavk | 4.95634 | 3.4789 | 2.08808 | 1.01233 | 0.87057 | -0.66102 |
| Popravljen normalizirani dobiček na enoto čistega dobička | 4.88712 | 3.90264 | 2.73926 | 1.01233 | 0.87057 | -0.66102 |
| Other Operating Expenses, Total | -7.377 | -0.763 | 0 | 0 | ||
| Skupaj izredne postavke | -3.4 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Skupni prihodki | 41.249 | 48.124 | 39.853 | 42.32 | 115.874 |
| Prihodki | 41.249 | 48.124 | 39.853 | 42.32 | 115.874 |
| Celotni stroški prihodkov | 10.855 | 10.757 | 8.259 | 12.309 | 27.755 |
| Bruto dobiček | 30.394 | 37.367 | 31.594 | 30.011 | 88.119 |
| Celotni odhodki iz poslovanja | 45.022 | 37.304 | 50.03 | 36.421 | 56.045 |
| Celotna prodaja/splošni/upravni stroški Odhodki | 19.879 | 16.636 | 18.482 | 20.325 | 22.182 |
| Raziskave in razvoj | 14.288 | 9.911 | 23.289 | 3.787 | 6.108 |
| Prihodki iz poslovanja | -3.773 | 10.82 | -10.177 | 5.899 | 59.829 |
| Prihodki (odhodki) od obresti, neto Neoperativni | 5.213 | -5.459 | -2.499 | -4.53 | -2.712 |
| Drugo, neto | -0.1 | 0.187 | 0.016 | -0.145 | 0.543 |
| Čisti dobiček pred obdavčitvijo | 1.34 | 5.548 | -12.66 | 1.224 | 57.66 |
| Čisti dobiček po davkih | -0.421 | 3.612 | -5.622 | -6.196 | 44.058 |
| Čisti dobiček pred dodatnimi postavkami | -0.421 | 3.612 | -5.622 | -6.196 | 44.058 |
| Čisti dobiček | -0.421 | 3.612 | -5.622 | -6.196 | 44.058 |
| Prihodek, ki je na razpolago navadnim delničarjem, brez dodatnih postavk | -0.421 | 3.612 | -5.622 | -6.196 | 44.058 |
| Prihodek, ki je na razpolago skupnemu dobičku, vključno z dodatnimi postavkami | -0.421 | 3.612 | -5.622 | -6.196 | 44.058 |
| Popravljen čisti dobiček | -0.421 | 3.612 | -5.622 | -6.196 | 44.058 |
| Popravljene ponderirane povprečne delnice | 13.0694 | 13.2622 | 13.0773 | 12.8948 | 12.9068 |
| Popravljen dobiček na delnico brez upoštevanja izrednih postavk | -0.03221 | 0.27235 | -0.42991 | -0.4805 | 3.41355 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Popravljen normalizirani dobiček na enoto čistega dobička | -0.03221 | 0.27235 | -0.42991 | -0.4805 | 3.41355 |
- Letni
- Četrtletno
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Kratkoročna sredstva skupaj | 109.11 | 188.697 | 163.844 | 179.449 | 166.065 | 172.606 |
| Denarna sredstva in kratkoročne naložbe | 52.82 | 114.657 | 78.791 | 109.775 | 103.155 | 97.659 |
| Denarna sredstva in ustrezniki | 52.82 | 114.657 | 78.791 | 109.775 | 103.155 | 97.659 |
| Celotne terjatve, neto | 42.194 | 53.821 | 66.486 | 48.004 | 51.117 | 41.149 |
| Accounts Receivable - Trade, Net | 42.194 | 53.821 | 66.486 | 48.004 | 51.117 | 41.149 |
| Total Inventory | 2.739 | 5.118 | 8.304 | 6.566 | 8.075 | 21.908 |
| Prepaid Expenses | 11.357 | 15.101 | 10.263 | 15.104 | 3.718 | 11.89 |
| Total Assets | 214.32 | 270.06 | 238.603 | 254.554 | 253.19 | 253.732 |
| Property/Plant/Equipment, Total - Net | 3.316 | 6.82 | 2.397 | 5.918 | 2.077 | 1.636 |
| Property/Plant/Equipment, Total - Gross | 4.822 | 9.258 | 5.744 | 10.237 | 7.268 | 7.591 |
| Accumulated Depreciation, Total | -1.506 | -2.438 | -3.347 | -4.319 | -5.191 | -5.955 |
| Goodwill, Net | 39.743 | 39.743 | 39.743 | 39.743 | 39.743 | 39.743 |
| Intangibles, Net | 33.372 | 23.322 | 18.103 | 15.583 | 12.917 | 10.671 |
| Other Long Term Assets, Total | 28.779 | 11.478 | 14.516 | 13.861 | 32.388 | 29.076 |
| Total Current Liabilities | 40.965 | 47.302 | 39.686 | 38.823 | 38.085 | 74.376 |
| Accounts Payable | 15.728 | 27.036 | 9.917 | 5.462 | 6.268 | 16.431 |
| Accrued Expenses | 23.549 | 15.391 | 23.519 | 28.361 | 23.817 | 32.338 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 1.688 | |||||
| Total Liabilities | 63.094 | 90.916 | 77.841 | 75.38 | 67.179 | 77.279 |
| Total Long Term Debt | 0 | 42.905 | 38.155 | 33.557 | 25.135 | 0 |
| Other Liabilities, Total | 22.129 | 0.709 | 0 | 3 | 3.959 | 2.903 |
| Total Equity | 151.226 | 179.144 | 160.762 | 179.174 | 186.011 | 176.453 |
| Common Stock | 0.016 | 0.016 | 0.017 | 0.017 | 0.017 | 0.017 |
| Additional Paid-In Capital | 213.872 | 233.639 | 256.458 | 278.518 | 305.403 | 325.779 |
| Retained Earnings (Accumulated Deficit) | -25.659 | 26.284 | 58.187 | 72.5 | 84.489 | 75.862 |
| Treasury Stock - Common | -37.003 | -80.795 | -153.9 | -171.861 | -203.898 | -225.111 |
| Total Liabilities & Shareholders’ Equity | 214.32 | 270.06 | 238.603 | 254.554 | 253.19 | 253.732 |
| Total Common Shares Outstanding | 15.324 | 14.8477 | 13.914 | 13.6302 | 13.057 | 12.7914 |
| Current Port. of LT Debt/Capital Leases | 4.875 | 6.25 | 5 | 8 | 25.607 | |
| Long Term Debt | 42.905 | 38.155 | 33.557 | 25.135 | 0 | |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | ||
| Other Equity, Total | -0.094 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Kratkoročna sredstva skupaj | 163.986 | 175.504 | 171.694 | 172.606 | 240.166 |
| Denarna sredstva in kratkoročne naložbe | 105.229 | 108.717 | 99.741 | 97.659 | 69.522 |
| Denarna sredstva in ustrezniki | 105.229 | 108.717 | 99.741 | 97.659 | 69.522 |
| Celotne terjatve, neto | 44.868 | 52.659 | 47.081 | 41.149 | 130.858 |
| Accounts Receivable - Trade, Net | 44.868 | 52.659 | 45.335 | 41.149 | 130.858 |
| Total Inventory | 6.862 | 8.294 | 9.315 | 21.908 | 24.818 |
| Prepaid Expenses | 7.027 | 5.834 | 15.557 | 11.89 | 14.968 |
| Total Assets | 259.968 | 264.242 | 256.261 | 253.732 | 320.165 |
| Property/Plant/Equipment, Total - Net | 2.27 | 1.967 | 1.775 | 1.636 | 1.627 |
| Property/Plant/Equipment, Total - Gross | 7.652 | 7.537 | 7.542 | 7.591 | 7.759 |
| Accumulated Depreciation, Total | -5.382 | -5.57 | -5.767 | -5.955 | -6.132 |
| Goodwill, Net | 39.743 | 39.743 | 39.743 | 39.743 | 39.743 |
| Intangibles, Net | 12.211 | 11.505 | 10.799 | 10.671 | 9.94 |
| Other Long Term Assets, Total | 41.758 | 35.523 | 32.25 | 29.076 | 28.689 |
| Total Current Liabilities | 41.973 | 44.664 | 48.431 | 74.376 | 101.642 |
| Accounts Payable | 12.559 | 11.136 | 12.717 | 16.431 | 14.509 |
| Accrued Expenses | 21.414 | 25.528 | 27.714 | 32.338 | 63.408 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 8 | 8 | 8 | 25.607 | 23.725 |
| Total Liabilities | 68.89 | 69.395 | 70.968 | 77.279 | 104.205 |
| Total Long Term Debt | 23.253 | 21.371 | 19.489 | 0 | 0 |
| Long Term Debt | 23.253 | 21.371 | 19.489 | 0 | |
| Other Liabilities, Total | 3.664 | 3.36 | 3.048 | 2.903 | 2.563 |
| Total Equity | 191.078 | 194.847 | 185.293 | 176.453 | 215.96 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.017 | 0.017 | 0.017 | 0.017 | 0.017 |
| Additional Paid-In Capital | 312.323 | 316.249 | 320.566 | 325.779 | 328.769 |
| Retained Earnings (Accumulated Deficit) | 84.068 | 87.68 | 82.058 | 75.862 | 119.92 |
| Treasury Stock - Common | -205.33 | -208.195 | -216.466 | -225.111 | -233.164 |
| Total Liabilities & Shareholders’ Equity | 259.968 | 264.242 | 256.261 | 253.732 | 320.165 |
| Total Common Shares Outstanding | 13.1455 | 13.0971 | 12.9446 | 12.7914 | 12.6971 |
| Other Equity, Total | -0.904 | -0.882 | -0.094 | 0.418 |
- Letni
- Četrtletno
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Čisti prihodki/začetna postavka | 81.453 | 51.943 | 31.903 | 14.313 | 11.989 | -8.627 |
| Denarna sredstva iz poslovanja | 53.207 | 58.919 | 52.384 | 55.986 | 49.497 | 28.219 |
| Denarna sredstva iz poslovanja | 0.641 | 0.932 | 1.155 | 2.131 | 0.872 | 0.764 |
| Amortization | 0.948 | 2.815 | 2.515 | 2.52 | 2.666 | 2.996 |
| Deferred Taxes | -30.116 | 17.289 | -2.468 | 0.152 | -1.511 | -3.618 |
| Nedenarne postavke | 8.975 | 15.509 | 27.168 | 22.478 | 34.665 | 27.167 |
| Cash Taxes Paid | 2.8 | 10.542 | 2.281 | 6.673 | 6.428 | 10.005 |
| Denarna sredstva Plačane obresti | 0.008 | 0.651 | 2.084 | 2.478 | 2.224 | 1.197 |
| Spremembe v obratnem kapitalu | -8.694 | -29.569 | -7.889 | 14.392 | 0.816 | 9.537 |
| Denarna sredstva pri naložbenju | -45.8 | -5.186 | -0.133 | -0.777 | -18.247 | -5.323 |
| Kapitalski izdatki | -15.84 | -5.186 | -0.133 | -0.777 | -0.747 | -0.323 |
| Celotne druge postavke denarnih tokov pri naložbenju | -29.96 | 0 | 0 | -17.5 | -5 | |
| Denarna sredstva pri financiranju | -33.67 | 8.104 | -88.117 | -24.225 | -37.87 | -28.392 |
| Postavke denarnega toka pri financiranju | -0.286 | -1.192 | -19.877 | -0.524 | -1.525 | -1.577 |
| Izdaja (odplačilo) delnic, neto | -33.384 | -39.454 | -64.49 | -17.701 | -31.345 | -18.815 |
| Neto sprememba denarnih sredstev | -26.263 | 61.837 | -35.866 | 30.984 | -6.62 | -5.496 |
| Izdaja (odplačilo) dolga, neto | 48.75 | -3.75 | -6 | -5 | -8 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -0.421 | 3.191 | -2.431 | -8.627 | 44.058 |
| Cash From Operating Activities | 10.478 | 19.071 | 20.138 | 28.219 | -16.611 |
| Cash From Operating Activities | 0.19 | 0.378 | 0.575 | 0.764 | 0.177 |
| Amortization | 0.706 | 1.412 | 2.118 | 2.996 | 0.731 |
| Deferred Taxes | 0.902 | 1.119 | -2.533 | -3.618 | -2.432 |
| Non-Cash Items | 1.378 | 10.989 | 17.689 | 27.167 | 6.616 |
| Cash Taxes Paid | 0.267 | 4.3 | 6.303 | 10.005 | 0.041 |
| Cash Interest Paid | 0.321 | 0.625 | 0.917 | 1.197 | 0.265 |
| Changes in Working Capital | 7.723 | 1.982 | 4.72 | 9.537 | -65.761 |
| Cash From Investing Activities | -5.384 | -5.269 | -5.274 | -5.323 | -0.168 |
| Capital Expenditures | -0.384 | -0.269 | -0.274 | -0.323 | -0.168 |
| Other Investing Cash Flow Items, Total | -5 | -5 | -5 | -5 | 0 |
| Cash From Financing Activities | -3.02 | -8.24 | -18.278 | -28.392 | -11.358 |
| Financing Cash Flow Items | -1.551 | -1.551 | -1.551 | -1.577 | -1.305 |
| Issuance (Retirement) of Stock, Net | 0.531 | -2.689 | -10.727 | -18.815 | -8.053 |
| Issuance (Retirement) of Debt, Net | -2 | -4 | -6 | -8 | -2 |
| Net Change in Cash | 2.074 | 5.562 | -3.414 | -5.496 | -28.137 |
| Ime vlagatelja | Vrsta vlagatelja | Odstotek neporavnanih obveznosti | Delnice v lasti | Sprememba delnic | Datum imetništva | Ocena prometa |
|---|---|---|---|---|---|---|
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 12.5072 | 1627920 | -81855 | 2022-09-30 | LOW |
| Tarriff (Scott L) | Individual Investor | 11.4696 | 1492872 | -7559 | 2023-01-23 | LOW |
| Janus Henderson Investors | Investment Advisor/Hedge Fund | 9.5251 | 1239779 | -197535 | 2022-09-30 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 7.3144 | 952026 | -59721 | 2022-12-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 5.9441 | 773682 | 3756 | 2022-09-30 | LOW |
| Brandes Investment Partners, L.P. | Investment Advisor | 3.5945 | 467857 | 3565 | 2022-09-30 | LOW |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 2.7333 | 355759 | 38083 | 2022-09-30 | LOW |
| Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 2.3911 | 311220 | 124347 | 2022-09-30 | MED |
| Quoniam Asset Management GmbH | Investment Advisor/Hedge Fund | 2.1943 | 285611 | -8383 | 2022-09-30 | MED |
| Renaissance Technologies LLC | Hedge Fund | 2.1073 | 274279 | 21300 | 2022-09-30 | HIGH |
| Adage Capital Management, L.P. | Hedge Fund | 1.9207 | 250000 | 0 | 2022-09-30 | LOW |
| Smith, Graham & Co. Investment Advisors, L.P. | Investment Advisor | 1.7765 | 231222 | -799 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.5104 | 196597 | 6749 | 2022-09-30 | LOW |
| Citadel Advisors LLC | Hedge Fund | 1.4218 | 185061 | 119741 | 2022-09-30 | HIGH |
| JP Morgan Asset Management | Investment Advisor | 1.3734 | 178763 | -5777 | 2022-09-30 | LOW |
| Millennium Management LLC | Hedge Fund | 1.2649 | 164643 | -150096 | 2022-09-30 | HIGH |
| Columbia Threadneedle Investments (US) | Investment Advisor/Hedge Fund | 1.251 | 162832 | -39873 | 2022-09-30 | LOW |
| Allspring Global Investments, LLC | Investment Advisor/Hedge Fund | 1.1573 | 150628 | 62456 | 2022-12-31 | LOW |
| Morgan Stanley & Co. LLC | Research Firm | 1.1521 | 149955 | 18647 | 2022-09-30 | MED |
| Charles Schwab Investment Management, Inc. | Investment Advisor | 1.0996 | 143124 | 20630 | 2022-09-30 | LOW |
Zakaj izbrati Capital.com? Številke govorijo same zase.
Capital.com Group +485000+
Borzni posredniki
65000+
Aktivne stranke mesečno
$48000000+
Mesečni obseg naložb
$28000000+
Preizkusi zdaj Dvigi vsak mesec
Kalkulator trgovanja
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trgovalna provizija
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Vzvod
20:1
- 20
- 100
- 500
- 1000
- 10000
Naložbe
Velikost posla (finančni vzvod x naložba):
Odpiranje
Zapiranje
Kratka Dolga
Eagle Pharm Company profile
O družbi Eagle Pharm
Eagle Pharmaceuticals, Inc. je integrirano farmacevtsko podjetje. Družba poskrbi, da se molekula od predkliničnih raziskav do regulativne odobritve in vstopa na trg, vključno z razvojem, proizvodnjo in trženjem. Družba opredeljuje zahtevna terapevtska področja bolezni osrednjega živčnega sistema ali presnovne kritične oskrbe ter onkologije, ki jih je treba zdraviti. Podjetje ponuja tri izdelke: Ryanodex, natrijev dantrolen) (Ryanodex), bendamustin, pripravljen za redčenje (RTD), 500 ml raztopine (Belrapzo), in hitro infundirani bendamustin RTD (Bendeka). Družba trži zdravila Ryanodex in Belrapzo, družba Teva Pharmaceutical Industries Ltd. (Teva) na Japonskem trži bendeko, liofilizirano praškasto obliko bendamustinovega hidroklorida.
| Industry: | Proprietary & Advanced Pharmaceuticals |
50 Tice Boulevard, Suite 315
WOODCLIFF LAKE
NEW JERSEY 07677
US
Izkaz poslovnega izida
- Annual
- Quarterly
Ljudje gledajo tudi
Še vedno iščete posrednika, ki mu lahko zaupate?
Pridružite se 485.000+ trgovcem po vsem svetu, ki so se odločili za trgovanje s Capital.com